Plasma levels of β2-microglobulin are associated with atherosclerosis in patients with systemic lupus erythematosus: a cross-sectional cohort study

Abstract

Objective

The objective of this paper is to examine the association between plasma levels of β2-microglobulin (β2MG), a protein previously associated with atherosclerosis, and the presence of carotid plaque (CP) or coronary artery calcium (CAC) in a cross-sectional cohort study of patients with systemic lupus erythematosus (SLE).

Methods

Patients with SLE were enrolled between June 2013 and May 2014. The presence of CP and CAC was assessed with ultrasonography and computed tomography scan, respectively. The presence of CP or CAC in the SLE patients was analyzed with respect to plasma levels of β2MG and renal function expressed as the estimated glomerular filtration rate (eGFR).

Results

The study cohort consisted of 147 patients, 89% women and 95% Caucasians. The median age was 46 (range: 21–75) years with a median disease duration of 14 years. CP and CAC was observed in 29 (20%) and 57 (39%) of patients, respectively. CP or CAC was seen in 62 (42%) patients and was associated with the highest quartile of plasma β2MG in patients with eGFR ≥ 90 ml/min/1.73 m²; OR = 18 (95% CI: 1.7–181). β2MG adjusted for eGFR was also associated with presence of CP or CAC in the total cohort. The exclusion of 25 patients with a prior history of cardiovascular disease did not change the observed associations.

Conclusion

In this study, we found significant associations between imaging markers of atherosclerosis and high plasma levels of plasma β2MG. These data suggest that β2MG is a candidate for further study as a biomarker for atherosclerosis in SLE.

Keywords

SLE atherosclerosis beta 2-microglobulin interferon cardiovascular disease

Get full access to this article

View all access options for this article.

References

Bengtsson

Ohman

Nived

Rantapää Dahlqvist

. Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study. Lupus 2012; 21: 452–459.

Björnådal

Yin

Granath

Klareskog

. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: Results from a Swedish population based study 1964–95. J Rheumatol 2004; 31: 713–719.

Hermansen

Lindhardsen

Torp-Pedersen

Faurschou

Jacobsen

. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: A Danish nationwide population-based cohort study. Rheumatology (Oxford) 2017; 56: 709–715.

Giannelou

Mavragani

. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. J Autoimmun 2017; 82: 1–12.

Evrin

Pertoft

. Beta2-microglobulin in human blood cells. J Immunol 1973; 111: 1147–1154.

Nesović-Ostojić

Klun

Vujanić

Trbovich

Djurković-Djaković

. Serum beta2-microglobulin as a marker of congenital toxoplasmosis and cytomegalovirus infection in preterm neonates. Neonatology 2008; 94: 183–186.

Lawn

Rudolph

Wiktor

Coulibably

Ackah

Lal

. Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and beta2-microglobulin, respectively. Clin Exp Immunol 2000; 122: 79–84.

Cooper

Plesner

. Beta-2-microglobulin review: Its relevance in clinical oncology. Med Pediatr Oncol 1980; 8: 323–334.

Kim

Jeon

Yoon

Suh

. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci 2010; 339: 337–340.

10.

Yeung

Wong

Chan

. beta 2-Microglobulin and systemic lupus erythematosus. J Rheumatol 1986; 13: 1053–1058.

11.

Evrin

Ström

. Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis 1984; 43: 267–274.

12.

Wibell

. Studies on beta2-microglobulin in patients and normal subjects. Acta Clin Belg 1976; 31: 14–26.

13.

Kim

Yun

Chun

et al.

Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. Diabetes Metab 2014; 40: 459–465.

14.

Wilson

Kimura

Harada

et al.

Beta2-microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies. Circulation 2007; 116: 1396–1403.

15.

Joosten

Pai

Bertoia

et al.

β2-microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease. J Am Heart Assoc 2014; 3: e000803–e000803.

16.

Safar

. Arterial stiffness: A simplified overview in vascular medicine. Adv Cardiol 2007; 44: 1–18.

17.

Safar

. Arterial stiffness and peripheral arterial disease. Adv Cardiol 2007; 44: 199–211.

18.

Kals

Zagura

Serg

et al.

β2-microglobulin, a novel biomarker of peripheral arterial disease, independently predicts aortic stiffness in these patients. Scand J Clin Lab Invest 2011; 71: 257–263.

19.

Saijo

Utsugi

Yoshioka

et al.

Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects. Hypertens Res 2005; 28: 505–511.

20.

Amighi

Hoke

Mlekusch

et al.

Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 2011; 42: 1826–1833.

21.

Prentice

Paczesny

Aragaki

et al.

Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med 2010; 2: 48–48.

22.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

23.

Gladman

Ibañez

Urowitz

. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.

24.

Gladman

Ginzler

Goldsmith

et al.

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

25.

Touboul

Hennerici

Meairs

et al.

Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 34: 290–296.

26.

Fuchs

Groen

Arnold

et al.

Assessment of coronary calcification using calibrated mass score with two different multidetector computed tomography scanners in the Copenhagen General Population Study. Eur J Radiol 2017; 88: 21–25.

27.

Agatston

Janowitz

Hildner

Zusmer

Viamonte

Jr Detrano

. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–832.

28.

Delgado

Pratt

Phillips

et al.

Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol 2009; 145: 801–805.

29.

Cockcroft

Gault

. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

30.

Du Bois

. A formula to estimate the approximate surface area if height and weight be known 1916. Nutrition 1989; 5: 303–311. discussion 312–303.

31.

Nived

Sturfelt

. Epidemiology of systemic lupus erythematosus. Monogr Allergy 1987; 21: 197–214.

32.

Manzi

Selzer

Sutton-Tyrrell

et al.

Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51–60.

33.

Groh

Keating

Joosten

LAB

Netea

Riksen

. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol 2018; 40: 203–214.

34.

Remes

Tienhaara

Pelliniemi

. Effects of alpha-interferon on serum beta-2-microglobulin. Leuk Lymphoma 1996; 21: 233–238.

35.

Cresswell

Springer

Strominger

Turner

Grey

Kubo

. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A 1974; 71: 2123–2127.

36.

Bengtsson

Rönnblom

. Role of interferons in SLE. Best Pract Res Clin Rheumatol 2017; 31: 415–428.

37.

Font

Coca

Molina

et al.

Serum beta 2-microglobulin as a marker of activity in systemic lupus erythematosus. Scand J Rheumatol 1986; 15: 201–205.

38.

Hermansen

Hummelshøj

Lundsgaard

et al.

Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus 2012; 21: 1098–1104.

39.

Denny

Thacker

Mehta

et al.

Interferon-alpha promotes abnormal vasculogenesis in lupus: A potential pathway for premature atherosclerosis. Blood 2007; 110: 2907–2915.

40.

Lee

Richards

et al.

Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3759–3769.

41.

Somers

Zhao

Lewis

et al.

Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012; 7: e37000–e37000.

42.

Hsu

Lin

et al.

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293–1302.

43.

Nadel

O’Dwyer

Emmanuel

et al.

High-risk coronary plaque, invasive coronary procedures, and cardiac events among HIV-positive individuals and matched controls. J Cardiovasc Comput Tomogr 2016; 10: 391–397.